Biocon: Japan Biosimilar Glargine Nod To Open Other Doors

India's largest biopharmaceutical company, Biocon, has reported quarterly net profit rocketed nearly 80% thanks to exceptional income, and says Japan's regulatory nod for its insulin glargine should help “fast-track” approvals of the biosimilar in both emerging markets and advanced economies.